Ansa Biotechnologies

ansabio.com →

+36%

est. 2Y upside i

HealthcareSeries B

Next-generation DNA synthesis using enzymes

Rank

#2211

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

Ansa offers real but heavily discounted employee equity upside due to a severe preference stack — $183.3M in cumulative funding against a $260.65M valuation means 70.3% of any exit value accrues to preferred investors before common equity participates.

Last updated: May 14, 2026

Bull (25%)+180%

Ansa achieves an IPO or strategic acquisition at $800M–$1B+ as enzymatic DNA synthesis captures 2–3% of the $6.1B SAM, with Microsoft validating the platform and revenue scaling to $70M+. After clearing $183.3M in liquidation preferences, employee common equity participates materially in the surplus, yielding ~180% on grant value.

Base (47%)+20%

Revenue grows to $35–45M by 2029–2030 at an 8–10x revenue multiple, implying a $350–450M enterprise value. After clearing $183.3M in liquidation preferences and absorbing dilution from at least one additional funding round, employee common equity sees a modest ~20% net gain.

Bear (28%)-65%

Intensifying competition from Twist Bioscience and well-funded incumbents, combined with very high capital intensity, forces a down round or distressed M&A below $200M. The severe $183.3M preference stack means employee common equity is largely wiped out, resulting in ~65% loss on grant value.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

70%

$183.3M in cumulative liquidation preferences sits against a $260.65M current valuation (70.3% coverage ratio), meaning a flat or modest exit leaves common stockholders with little to no proceeds.

Dilution Risk

high

As a capital-intensive Series B biotech with undisclosed profitability and very high ongoing capital needs, at least one additional large funding round is likely before any liquidity event, further diluting current common equity holders.

Secondary Liquidity

none

No secondary market signals detected for Ansa; Series B biotech equity is typically illiquid until IPO or M&A, both of which appear 4–6 years out given no disclosed IPO or M&A signals.

View all 6 open roles at Ansa Biotechnologies →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Ansa Biotechnologies's data — designed to show you've done your homework.

  • 1

    “With Twist Bioscience and Integrated DNA Technologies actively competing on price, how does Ansa's enzymatic synthesis technology defend its premium at volume scale, and what is the gross margin profile at the current $17.5M revenue run rate?”

  • 2

    “What is the revenue split between research/academic and commercial/industrial customers, and how does average contract value trend as sequence lengths and order complexity increase toward the 50kb product?”

  • 3

    “Given $183.3M in total funding at a $260.65M valuation, what is the board's targeted Series C timeline and preferred exit path — IPO, strategic acquisition, or sustained private growth — and how does the option or RSU vesting cliff align with those milestones?”

Community

Valuation Sentiment

Our model estimates +36% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.